CFO
IOVA icon

CVA Family Office’s Iovance Biotherapeutics IOVA Stock Holding History

CVA Family Office’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63
Closed -$592 – 1316
2024
Q3 		$592 Buy
+63
New +$597 ﹤0.01% 1166

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

CVA Family Office's IOVA Position: Q4 2024 in Review

CVA Family Office sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 63 shares — an estimated $592 sold.

CVA Family Office first reported a position in IOVA in Q3 2024 and held it in 1 quarter. The position peaked at $592 in Q3 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • CVA Family Office reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 63 Iovance Biotherapeutics shares in Q4 2024, an estimated $592.
  • CVA Family Office first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 1 quarter.
  • CVA Family Office's Iovance Biotherapeutics position peaked at $592 in Q3 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.